Briacell Therap (NASDAQ:BCTX) Stock Price Up 1.1% – Time to Buy?

Shares of Briacell Therap (NASDAQ:BCTX) shot up 1.1% during trading on Tuesday . The company traded as high as $3.65 and last traded at $3.63. Approximately 109,117 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 623,734 shares. The stock had previously closed at $3.59.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Briacell Therap Trading Up 1.1%

The company has a market capitalization of $31.58 million, a PE ratio of -0.46 and a beta of 1.09. The company has a fifty day simple moving average of $3.55 and a 200-day simple moving average of $3.74.

Briacell Therap (NASDAQ:BCTX) last announced its quarterly earnings results on Tuesday, June 9th. The company reported ($0.99) earnings per share for the quarter.

Institutional Trading of Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC bought a new stake in Briacell Therap (NASDAQ:BCTX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned 1.63% of Briacell Therap as of its most recent SEC filing. Hedge funds and other institutional investors own 15.42% of the company’s stock.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.